Ablavi Agomessou, APRN
Psychiatric/Mental Health · Lawrenceville, GANPI 1164885778
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,903, more than ten times the $113 reported in 2021. Among psychiatric/mental health clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$842
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$743
- Teva Pharmaceuticals USA, Inc.$615
- Neurocrine Biosciences, Inc.$499
- AbbVie$298
- Otsuka America Pharmaceutical, Inc.$296
- plus $1K from 12 others
What the payments were for
- Food & beverage$4,64698%
- Education$912%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 40 | $842 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $743 |
| Teva Pharmaceuticals USA, Inc. | 41 | $615 |
| Neurocrine Biosciences, Inc. | 31 | $499 |
| AbbVie | 15 | $298 |
| Otsuka America Pharmaceutical, Inc. | 16 | $296 |
| Corium, LLC | 15 | $285 |
| Alkermes, Inc. | 11 | $253 |
| Johnson & Johnson | 6 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $196 |
| Lundbeck LLC | 9 | $185 |
| E.r. Squibb & Sons, L.L.C. | 6 | $133 |
| OWP Pharmaceuticals, Inc. | 3 | $59 |
| Sunovion Pharmaceuticals Inc. | 3 | $41 |
| Tris Pharma Inc | 2 | $35 |
| Indivior Inc. | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Neos Therapeutics, LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$107
How this compares
$4,738 in reported general payments places this provider in the 90th percentile of 900 psychiatric/mental health providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 110 | $376,599 |
| Invega TrinzaPaliperidone Palmitate | 32 | $318,366 |
| RexultiBrexpiprazole | 113 | $178,394 |
| AustedoDeutetrabenazine | 19 | $134,912 |
| IngrezzaValbenazine Tosylate | 14 | $108,705 |
| Abilify AsimtufiiAripiprazole | 12 | $68,294 |
| Austedo XrDeutetrabenazine | 13 | $66,594 |
| VraylarCariprazine Hcl | 38 | $54,506 |
| CaplytaLumateperone Tosylate | 22 | $37,704 |
| Abilify MaintenaAripiprazole | 11 | $30,168 |
| Lurasidone Hcl | 90 | $19,528 |
| TrintellixVortioxetine Hydrobromide | 34 | $18,215 |
| BelsomraSuvorexant | 21 | $12,343 |
| Clozapine OdtClozapine | 15 | $9,801 |
| Paliperidone ErPaliperidone | 41 | $4,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $200 | $694,965142 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Asimtufii, Abilify Maintena | $296 | $276,856136 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $615 | $201,50532 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $499 | $108,70514 claims |
| AbbVieVraylar | $298 | $54,50638 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $743 | $37,70422 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $196 | $18,21534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 900 psychiatric/mental health providers in Georgia.
Other psychiatric/mental health in Lawrenceville
- Phyillis Kennedy-HowellBarney$673K
- Jessica OliverThomasville$233K
- Sherri KrollBrunswick$155K
- Taylor LeblancAlbany$48K
- Greta HeckmannDalton$28K
- Matthew DowdyWoodstock$25K
- Natasha GilesLoganville$21K
- Darrick SealeyWarner Robins$17K
- Olufunke AdewunmiSmyrna$13K
- Bradley MosherSuwanee$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.